Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 15/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25892607 | 0.81 | ITGA4 (0.55) | ITGA4AKR1A1AKR1B1BRD4 | |
| SCHEMBL19754247 | 0.78 | BRD4 (0.53) | BRD4BRD2BRD3BRDTNR3C1 | |
| SCHEMBL19754222 | 0.78 | BRD4 (0.53) | BRD4BRD2BRD3BRDTNR3C1 | |
| SCHEMBL25892639 | 0.77 | ITGA4 (0.58) | ITGA4AKR1A1AKR1B1 | |
| SCHEMBL25892604 | 0.76 | ITGA4 (0.57) | ITGA4AKR1A1AKR1B1PGR | |
| SCHEMBL21095641 | 0.75 | ITGA4 (0.73) | ITGA4AKR1A1AKR1B1 | |
| SCHEMBL20845783 | 0.74 | ITGA4 (0.55) | ITGA4AKR1A1AKR1B1 | |
| SCHEMBL21095592 | 0.74 | ITGA4 (0.61) | ITGA4AKR1A1AKR1B1 | |
| SCHEMBL20845780 | 0.74 | ITGA4 (0.57) | ITGA4AKR1A1AKR1B1 | |
| SCHEMBL25063678 | 0.73 | ITGA4 (0.60) | ITGA4AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2023-02-23 | — | — | US | disclosed |
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2019060720-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1A1 8/4885AKR1B1 9/4885 |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | ITGA4 4749/4885AKR1A1 3/4885AKR1B1 1/4885 |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1A1 8/4885AKR1B1 9/4885 |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | ITGA4 4739/4885AKR1A1 3/4885AKR1B1 1/4885 |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1A1 8/4885AKR1B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.